PUBLISHED WORK

Selected publications -

for a full list, please click here

A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8

Rodriguez-Rodriguez BA, Ciabattoni G, Duerr R, Valero-Jimenez AM, Yeung ST, Crosse KM, Schinlever AR, Bernard-Raichon L, Rodriguez Galvan JJ, McGrath M, Vashee S, Xue Y, Loomis C, Khanna KM, Cadwell K, Desvignes L, Frieman MB, Ortigoza MB, Dittmann M.

Nat Commun 2023, 14, 3026

Bruno's thesis work and Grace's first co-first author paper establishes a mouse model for SARS-CoV-2 transmission and identifies a role for ORF8 in allowing robust viral shedding from the upper respiratory tracts. Wonderful collaboration with the fantastic Dr. Mila Ortigoza.

Antiviral DExD/H-box helicase 60 selectively reduces translation off type II internal ribosome entry sites

Sadic M, Schneider WM, Katsara O, Medina GN, Fisher A, Mogulothu A, Yu Y, Gu M, de los Santos T, Schneider RJ, Dittmann M

EMBO Rep 2022 23:e55218

Mohammad's thesis work finally clarifies the role of DDX60 as a directly antiviral interferon-stimulated effector.

Long non-coding RNA CHROMR regulates antiviral immunity in humans

van Solingen C, Cyr Y, Scacalossi KR, de Vries M, Barrett TJ, de Jong A, Gourvest M, Zhang T, Kher R, Cornwell M, Gildea MA, Brown EJ, Fanucchi S, Mhlanga MM, Berger JS, Dittmann M, Moore KJ

PNAS 2022 119(37):e2210321119

We teamed up with Dr. Katherine Moore's lab to characterize a new long non-coding RNA regulating ISG expression.

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, Bloom JD, Bloyet LM, Bonenfant G, Boon ACM, Boritz EA, Bratt DL, Bricker TL, Brown L, Buchser WJ, Carreño JM, Cohen-Lavi L, Darling TL, Davis-Gardner ME, Dearlove BL, Di H, Dittmann M, Doria-Rose NA, Douek DC, Drosten C, Edara VV, Ellebedy A, Fabrizio TP, Ferrari G, Florence WC, Fouchier RAM, Franks J, García-Sastre A, Godzik A, Gonzalez-Reiche AS, Gordon A, Haagmans BL, Halfmann PJ, Ho DD, Holbrook MR, Huang Y, James SL, Jaroszewski L, Jeevan T, Johnson RM, Jones TC, Joshi A, Kawaoka Y, Kercher L, Koopmans MPG, Korber B, Koren E, Koup RA, LeGresley EB, Lemieux JE, Liebeskind MJ, Liu Z, Livingston B, Logue JP, Luo Y, McDermott AB, McElrath MJ, Meliopoulos VA, Menachery VD, Montefiori DC, Mühlemann B, Munster VJ, Munt JE, Nair MS, Netzl A, Niewiadomska AM, O'Dell S, Pekosz A, Perlman S, Pontelli MC, Rockx B, Rolland M, Rothlauf PW, Sacharen S, Scheuermann RH, Schmidt SD, Schotsaert M, Schultz-Cherry S, Seder RA, Sedova M, Sette A, Shabman RS, Shen X, Shi PY, Shukla M, Simon V, Stumpf S, Sullivan NJ, Thackray LB, Theiler J, Thomas PG, Trifkovic S, Türeli S, Turner SA, Vakaki MA, van Bakel H, VanBlargan LA, Vincent LR, Wallace ZS, Wang L, Wang M, Wang P, Wang W, Weaver SC, Webby RJ, Weiss CD, Wentworth DE, Weston SM, Whelan SPJ, Whitener BM, Wilks SH, Xie X, Ying B, Yoon H, Zhou B, Hertz T, Smith DJ, Diamond MS, Post DJ, and Suthar MS .

Nature 2022 May;605(7911):640-652

This article highlights work within the NIH SAVE (SARS-CoV-2 assessment of viral evolution) consortium. The Dittmann lab is part of both the "early detection" group and the "in vivo characterization" group.

A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19

de Vries M., Mohamed A.S., Prescott R.A., Valero-Jimenez A.M., Desvignes L., O'Connor R., Steppan C., Devlin J.C., Ivanova E., Herrera A., Schinlever A., Loose P., Ruggles K., Koralov S.B., Anderson A.S., Binder J., and Dittmann M.

J. Virol. 2021 DOI: 10.1128/JVI.01819-20 Spotlight article

We characterize the first-in-class protease inhibitor for SARS-CoV-2 that went into clinical trials and was the predecessor of the active component of the now successful antiviral drug "Paxlovid".

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

Lokugamage K.G., Hage A., de Vries M., Valero-Jimenez A.M., Schindewolf C., Dittmann M.,Rajsbaum R., Menachery V.D.

J Virol. 2020 Nov 9;94(23) Spotlight Article, J. Virol. 2020 most cited article list

Together with Dr. Vineet Menachery and Dr. Ricardo Rajsbaum's lab, we show that while SARS-CoV potently escapes both innate immune detection and the consequences of IFN signaling, SARS-CoV-2 has lost its ability to escape the effects of IFN.

The regulatory factor ELF1 triggers a critical wave of transcription in the antiviral response to type I interferon

Seifert LL*, Si C*, Saha D, Sadic M, de Vries M, Ballentine S, Briley A, Wang G, Valero-Jimenez A, Mohamed A, Schaefer U, Moulton H, García-Sastre A, Tripathi S, Rosenberg BR, Dittmann M.

PLOS Pathogens 2019, doi.org/10.1371/journal.ppat.1007634

We show that the transcription factor ELF1 provides an additional layer of the innate host response, independent from the action of type I interferons.